KIT Is a frequent target for epigenetic silencing in cutaneous melanoma

Journal of Investigative Dermatology

Volumn 135, Issue 2, 2015, Pages 516-524

  Dahl, Christina ^a   Abildgaard, Cecilie ^a   Riber Hansen, Rikke ^b   Steiniche, Torben ^b   Lade Keller, Johanne ^b   Guldberg, Per ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; ARF PROTEIN; B RAF KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DECITABINE; MESSENGER RNA; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; STEM CELL FACTOR; TRANSCRIPTION FACTOR AP 2; STEM CELL FACTOR RECEPTOR;

ARTICLE; CELL GROWTH; COMPARATIVE STUDY; CONTROLLED STUDY; CPG ISLAND; CUTANEOUS MELANOMA; DNA METHYLATION; EPIGENETICS; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MELANOCYTE; MELANOMA CELL LINE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN TARGETING; TRANSCRIPTION INITIATION SITE; ANTAGONISTS AND INHIBITORS; GENETIC EPIGENESIS; GENETICS; MELANOMA; PHYSIOLOGY; SKIN TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; MELANOMA; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-KIT; SKIN NEOPLASMS; STEM CELL FACTOR;

EID: 84924612133     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.372     Document Type: Article

References (47)

1. Curtin JA, Busam K, Pinkel D et al. (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340-6
2. Dahl C, Christensen C, Jönsson G et al. (2013) Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14ARF and RARbeta signaling. Mol Cancer Res 11:1166-78
3. Dahl C, Guldberg P (2007) The genome and epigenome of malignant melanoma. APMIS 115:1160-75
4. Du P, Zhang X, Huang CC et al. (2010) Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 11:587
5. Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30:207-10
6. Enguita-German M, Gurrea M, Schiapparelli P et al. (2011) KIT expression and methylation in medulloblastoma and PNET cell lines and tumors. J Neurooncol 103:247-53
7. Felicetti F, Errico MC, Bottero L et al. (2008) The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 68:2745-54
8. Funasaka Y, Boulton T, Cobb M et al. (1992) c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas. Mol Biol Cell 3:197-209
9. Furuta J, Nobeyama Y, Umebayashi Y et al. (2006) Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. Cancer Res 66:6080-6
10. Gao L, Smit MA, van den Oord JJ et al. (2013) Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma. Pigment Cell Melanoma Res 26:542-54
11. Grichnik JM (2008) Melanoma, nevogenesis, and stem cell biology. J Invest Dermatol 128:2365-80
12. Guldberg P, Thor Straten P, Birck A et al. (1997) Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57:3660-3
13. Guo J, Si L, Kong Y et al. (2011) Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 29:2904-9
14. Gutman M, Singh RK, Radinsky R et al. (1994) Intertumoral heterogeneity of receptor-tyrosine kinases expression in human melanoma cell lines with different metastatic capabilities. Anticancer Res 14:1759-65
15. Haass NK, Herlyn M (2005) Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc 10:153-63
16. Han H, Cortez CC, Yang X et al. (2011) DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. Hum Mol Genet 20:4299-310
17. Heinrich MC, Corless CL, Demetri GD et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-9
18. Hodi FS, Corless CL, Giobbie-Hurder A et al. (2013) Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 31:3182-90
19. Huang S, Jean D, Luca M et al. (1998) Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J 17:4358-69
20. Huang S, Luca M, Gutman M et al. (1996) Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene 13:2339-47
21. Igoucheva O, Alexeev V (2009) MicroRNA-dependent regulation of cKit in cutaneous melanoma. Biochem Biophys Res Commun 379:790-4
22. Imokawa G (2004) Autocrine and paracrine regulation of melanocytes in human skin and in pigmentary disorders. Pigment Cell Res 17:96-110
23. Issa JP (2004) CpG island methylator phenotype in cancer. Nat Rev Cancer 4:988-93
24. Jönsson G, Dahl C, Staaf J et al. (2007) Genomic profiling of malignant melanoma using tiling-resolution array CGH. Oncogene 26:4738-48
25. Koga Y, Pelizzola M, Cheng E et al. (2009) Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res 19:1462-70
26. Lade-Keller J, Riber-Hansen R, Guldberg P et al. (2013) E- to N-cadherin switch in melanoma is associated with decreased expression of phosphatase and tensin homolog and cancer progression. Br J Dermatol 169:618-28
27. Lassam N, Bickford S (1992) Loss of c-kit expression in cultured melanoma cells. Oncogene 7:51-6
28. Lennartsson J, Rönnstrand L (2012) Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev 92:1619-49
29. Levy C, Khaled M, Fisher DE (2006) MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 12:406-14
30. Lin JY, Fisher DE (2007) Melanocyte biology and skin pigmentation. Nature 445:843-50
31. Montone KT, Van Belle P, Elenitsas R et al. (1997) Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol 10:939-44
32. Natali PG, Nicotra MR, Winkler AB et al. (1992) Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer 52:197-201
33. Serrano M, Lin AW, McCurrach ME et al. (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88:593-602
34. Shen SS, Zhang PS, Eton O et al. (2003) Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J Cutan Pathol 30:539-47
35. Siemens H, Jackstadt R, Kaller M et al. (2013) Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget 4:1399-415
36. Tanemura A, Terando AM, Sim MS et al. (2009) CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 15:1801-7
37. Tsao AS, Kantarjian H, Cortes J et al. (2003) Imatinib mesylate causes hypopigmentation in the skin. Cancer 98:2483-7
38. Tsao H, Chin L, Garraway LA et al. (2012) Melanoma: from mutations to medicine. Genes Dev 26:1131-55
39. Van Raamsdonk CD, Griewank KG, Crosby MB et al. (2010) Mutations in GNA11 in uveal melanoma. N Engl J Med 363:2191-9
40. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10:789-99
41. Weber M, Davies JJ, Wittig D et al. (2005) Chromosome-wide and promoterspecific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 37:853-62
42. White RM, Zon LI (2008) Melanocytes in development, regeneration, and cancer. Cell Stem Cell 3:242-52
43. Whiteman DC, Pavan WJ, Bastian BC (2011) The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 24:879-97
44. Worm J, Aggerholm A, Guldberg P (2001) In-tube DNA methylation profiling by fluorescence melting curve analysis. Clin Chem 47:1183-9
45. Worm J, Christensen C, Grønbæk K et al. (2004) Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene 23: 5215-26
46. Zakut R, Perlis R, Eliyahu S et al. (1993) KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells. Oncogene 8:2221-9
47. Zhu YI, Fitzpatrick JE (2006) Expression of c-kit (CD117) in Spitz nevus and malignant melanoma. J Cutan Pathol 33:33-7